Pfizer Raises 2026 Revenue and EPS Guidance Amid Strong Product Growth
Pfizer (PFE) has upgraded its financial outlook for 2026, now projecting annual revenue between $62 billion and $64 billion. The company also raised its adjusted earnings per share (EPS) guidance to a range of $2.95 to $3.05. Management attributed the positive revision to strong commercial execution, specifically noting a 32% operational revenue growth in the current quarter driven by newly launched and acquired products. Looking further ahead, Pfizer is targeting a high single-digit revenue compound annual growth rate (CAGR) for the period between 2028 and 2033.
Tickers: $PFE
Topics: earnings pharmaceuticals revenue growth